E-Therapeutics PLC
LSE:ETX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
E-Therapeutics PLC
Net Income (Common)
E-Therapeutics PLC
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E-Therapeutics PLC
LSE:ETX
|
Net Income (Common)
-ÂŁ8.3m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-7%
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Net Income (Common)
-$235.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-116%
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Net Income (Common)
-$224.8m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Net Income (Common)
-ÂŁ51.1m
|
CAGR 3-Years
27%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Net Income (Common)
ÂŁ19.3m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Net Income (Common)
-ÂŁ37.1m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-14%
|
|
E-Therapeutics PLC
Glance View
e-Therapeutics Plc is a drug discovery and development company, which engages in the provision of evaluation services to investors and pharmaceutical companies. The company is headquartered in Witney, Oxfordshire and currently employs 18 full-time employees. The company went IPO on 2007-11-28. The firm's platform is a combination of databases and a suite of computational tools that employ network analysis, data mining, machine learning, artificial intelligence (Al) and optimization. Its in silico platform serves as a laboratory, which enables it to computationally test potential therapeutic interventions. Its network-driven drug discovery (NDD) technology performs computational phenotypic screens to identify efficacious drugs. Its genome-associated interactions networks (GAINs) technology interprets genomic data in the context of the biological networks, in which the genes function. Its ribonucleic acid (RNA) Interference, (RNAi) platform is in development to complement its computational toolset. The firm identifies new therapeutic approaches to modulate a specific mechanism involved in Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic indications through Galapagos NV (Galapagos).
See Also
What is E-Therapeutics PLC's Net Income (Common)?
Net Income (Common)
-8.3m
GBP
Based on the financial report for Jan 31, 2023, E-Therapeutics PLC's Net Income (Common) amounts to -8.3m GBP.
What is E-Therapeutics PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-7%
Over the last year, the Net Income (Common) growth was -3%. The average annual Net Income (Common) growth rates for E-Therapeutics PLC have been -52% over the past three years , -9% over the past five years , and -7% over the past ten years .